Khiron Life Sciences Corp.
KHRNH.V
TSX
| 09/30/2022 | 06/30/2022 | 03/31/2022 | 12/31/2021 | 09/30/2021 | |
|---|---|---|---|---|---|
| Revenue | -7.14% | 53.57% | 63.72% | 49.26% | 93.04% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -7.14% | 53.57% | 63.72% | 49.26% | 93.04% |
| Cost of Revenue | -1.99% | 108.59% | 146.91% | 220.48% | 80.63% |
| Gross Profit | -11.98% | 24.07% | -4.23% | -73.89% | 106.40% |
| SG&A Expenses | -20.69% | -26.89% | -11.02% | 3.60% | -11.87% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -18.11% | -2.14% | 16.01% | 109.31% | 1.23% |
| Operating Income | 26.50% | 35.63% | 8.60% | -180.54% | 25.76% |
| Income Before Tax | 0.13% | 55.80% | 1.51% | -808.90% | 47.51% |
| Income Tax Expenses | 11,875.00% | -380.70% | 14.55% | -544.36% | 115.38% |
| Earnings from Continuing Operations | -3.45% | 56.44% | 1.49% | -748.99% | 47.44% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.45% | 56.44% | 1.49% | -748.99% | 47.44% |
| EBIT | 26.50% | 35.63% | 8.60% | -180.54% | 25.76% |
| EBITDA | 28.55% | 40.28% | 11.36% | -174.23% | 30.16% |
| EPS Basic | 14.67% | 64.86% | 17.36% | -517.14% | 64.95% |
| Normalized Basic EPS | 20.21% | 63.52% | 17.22% | -80.95% | 64.93% |
| EPS Diluted | 3.77% | 64.86% | 24.68% | -517.14% | 64.67% |
| Normalized Diluted EPS | 20.21% | 63.52% | 17.22% | -80.95% | 64.93% |
| Average Basic Shares Outstanding | 21.18% | 23.45% | 19.03% | 37.31% | 50.48% |
| Average Diluted Shares Outstanding | 21.18% | 23.45% | 19.03% | 37.31% | 50.48% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
